text:
MRC TechWatch
Norah O'Donnell Leana Wen Ilhan Omar Trump Coverage Studies
As Susan Rice Withdrew, Networks Kept Denying She Lied on TV -- Republicans Only 'Seemed to Believe She Misled the Nation'
By Tim Graham | December 15, 2012 4:35 PM EST
On Thursday night, when UN Ambassador Susan Rice withdrew her name from consideration to be Secretary of State, the nation's broadcast network struggled again with the facts: Rice lied on five Sunday shows in stark contrast with reality that there was no premeditated terrorist attack on the consulate in Benghazi. Instead, they insisted the truth was only something Republicans claimed.
Take NPR anchor Audie Cornish: "Rice had long been a leading contender to succeed Hillary Clinton who has said she would like to step down early next year. But a chorus of Republican senators who believe Rice misled the nation about the attack on the U.S. Consulate in Libya made clear they would fight her nomination." They believe she misled?? Cornish wasn't alone:
There was PBS NewsHour anchor Hari Sreenivasan: "Rice has come under criticism from congressional Republicans for not immediately calling the attack on the U.S. Consulate in Benghazi, Libya, a terrorist action. In her letter, Rice wrote: 'The position of secretary of state should never be politicized. I'm saddened that we have reached this point.'"
On the CBS Evening News, Rice was merely challenged on her accuracy:
BILL PLANTE: Republicans challenged Rice's explanation of the September 11th attack on the U.S mission in Benghazi, Libya that killed ambassador Chris Stevens and three others. Five days after that attack Rice appeared on "Face the Nation."
SUSAN RICE: We do not have information at present that leads us to conclude that this was premeditated or preplanned.
PLANTE: Republicans led by John McCain charged that the administration already knew that it was a planned terrorist attack.
MCCAIN: It is clear that the information that she gave the American people was incorrect.
On ABC's World News, the usually straight-shooting Jake Tapper seemed entranced by the same denying-the-obvious talking points, as if he was ABC's version of Susan Rice:
DIANE SAWYER: We begin with breaking news. The woman who withstood ferocious fire from political opponents in Washington today said enough. Susan Rice, the ambassador to the UN, so embattled over the tragedy in Benghazi said she will not go through a bruising nomination fight to succeed Hillary Clinton as secretary of state.
JAKE TAPPER: ...Just weeks ago, Rice, a tough and smart rising star in the Obama administration, was the President's top choice to serve as the next secretary of state. But she drew a lightning storm of Republican criticism for repeating talking points from the intelligence committee that seemed to critics to downplay the terrorist attack on the diplomatic compound in Benghazi, Libya. (He included a soundbite of McCain saying her information was "incorrect.")
"Seemed to critics to downplay the terrorist attack"!? She didn't downplay a terrorist attack, she DENIED there was a terrorist attack. The next morning on Good Morning America, Tapper put on Rice's lie and still fudged it.
RICE: In fact, what this began as was a spontaneous, not a premeditated response.
JAKE TAPPER: Five days after those attacks, Rice went on the Sunday shows, repeating talking points from the intelligence community that critics said downplayed the terrorist attack in the weeks leading up to the election.
SUSAN RICE: I didn't mislead. I didn't misrepresent. I did the best with the information that the United States government had at the time.
JAKE TAPPER: Democrats point out that Republicans didn't have such a difficult time with a different national security adviser named Rice, who had different inaccurate talking points from the intelligence community. Of course, that was Condoleezza Rice talking about Iraqi weapons of mass destruction that did not exist. That was a different time.
On NBC Nightly News, Brian Williams was boasting about his exclusive interview with Rice. They tried to avoid the obvious five-network lie angle. Williams asked Rice: "Why was it you that, Sunday morning, of all the people in government? Why the U.S. ambassador to the United Nations answering questions about the attack in Benghazi?"
It wasn't "Why did you lie?" It was "Why did they send you to lie?"
Then NBC's Andrea Mitchell painted Rice's friends as a bit dim: "Susan Rice's many defenders, Brian, are trying to figure out how Republicans managed to deny the president his top choice for secretary of state without benefit of a nomination or a hearing." There was that lying-on-five-network-Sunday-shows thing....
Then Mitchell blamed McCain as seeking retribution:
ANDREA MITCHELL: Rice`s trouble began with those Sunday show appearances in September on Benghazi, what looked like a job audition to become secretary of state.
SUSAN RICE: What happened in Benghazi was, in fact, initially a spontaneous reaction to what had just transpired hours before in Cairo.
MITCHELL: Her comments were based on CIA talking points that proved wrong. It was a terror attack, not a protest. Republicans accused Rice of twisting the facts to play politics. The president dramatically defended her.
PRESIDENT OBAMA: If Senator McCain and Senator Graham and others want to go after somebody, they should go after me.
MITCHELL: But Rice was in limbo, not officially nominated but being buried under an avalanche of leaks.
RICE: I relied solely and squarely on the information provided to me by the intelligence community. I made clear that the information was preliminary.
MITCHELL: Rice`s request to meet with the Republican critics backfired horribly.
SEN. LINDSEY GRAHAM: Bottom line, I`m more disturbed now than I was before.
SEN. JOHN MCCAIN: We are significantly troubled by many of the answers that we got and some that we didn`t get.
MITCHELL: For John McCain, many say, it was personal. Rice had derided his Iraq policy during the 2008 campaign.
I looked at CNN's Situation Room and Anderson Cooper 360, but both focused on the politics of what happens next, and neither recounted the inaccurate Sunday-show interviews.
Tim Graham is Executive Editor of NewsBusters and is the Media Research Center's Director of Media Analysis
REVIEW: Unmasked' Book Shows How Brent Bozell Fought the Media State and Won
MRC's Brent Bozell in PragerU Video: Social Media Is Becoming 'Orwellian' 'Big Brother'
About NewsBusters
MRC Action
Support NewsBusters
Support MRC Business
Support MRC Culture
Support MRC Latino
© 2005-2019, Media Research Center. All Rights Reserved.


text:
Still Hung Up on Click-Throughs?
It's 2001, and online marketing is no longer a new phenomenon, though we still seem to treat it like one.
For the past two years advertisers, publishers and agencies have struggled with strategies and technologies to turn this unique medium into the definitive marketing tool that it should be. They haven't found the grail, and the jury that has been out on the effectiveness of online advertising is getting cranky. They've got the wrong guy. The problem is not the medium — it's the way we've been using and measuring it.
Despite the recent press, online advertising is here to stay. And it's set to become a growing slice of a broader digital marketing boom estimated at $63 billion by 2005, according to Forrester Research's January 2001 report "Online Advertising Eclipsed." In fact, online marketing budgets are set to double by 2003. With all this promise, isn't it about time marketers put click-throughs to rest and started taking a more meaningful approach to measuring the results of these large investments?
Once upon a time, click-through rates were considered the best standard for measuring the performance of an online ad. Click-throughs, however, much like TV's Nielsen ratings, show only how many people view an ad. At a stage in our digital evolution when driving traffic to a Web site was critical to a business' valuation, this was considered a valid tool — except that users got frustrated with being forcibly dragged to URLs by these ads and became loath to click on them. Over time, click-through rates have shrunk to 0.25 percent, according to the Interactive Advertising Bureau, down from 8 percent five years ago.
Enter interactive and rich media ads as a means of creating more dynamic user experiences. The word "ads" doesn't capture what these things can do. They are capable of anything that a Web site can offer with call-to-action features like video and sound. These features entice surfers to interact, and fulfillment technologies allow them to conduct transactions within the ad itself.
Sure, it has taken marketers and their agencies time to figure out the best technologies and execution. Even today, this learning curve continues as technologies for the creation, targeting, optimization and measurement of rich media ads become dramatically more powerful. To borrow from Mr. Kent (Superman's dad), "with great power comes great responsibility," or in this case, great amounts of information, new kinds of information that require a higher and more thorough understanding of what users are doing as they interact with digital marketing.
With the acceptance of rich media, a shift has begun in the measurement and valuation world. Companies are beginning not only to measure traffic but also customer interaction and acquisition. For example, did a potential customer sign up for e-mail, a newsletter, enter a contest or register for custom stock prices to be sent to his inbox? This important transactive element provides marketers with deeper customer data and behavioral patterns enabling them to further marketing efforts. And so, cost per acquisition became an important new measurement standard alongside click-throughs, enabling marketers to witness more meaningful return on investment.
However, for many Fortune 1000 marketers still grappling with online marketing strategies, this is still not enough to justify the millions of dollars being spent. While measuring customer acquisition is a move in the right direction, we must start examining "customer share" as a truer evaluation of the effectiveness of online marketing. By customer share, I mean a definitive and continuing connection with a customer. This can be measured by the percentage of purchasing or transacting a client performs at a site following his or her interaction with an ad.
Take Amazon, for example, which learned early on that there was only so much share of each customer it could get with books. Customers would go elsewhere to buy gadgets, gifts, CDs. To get more customer share from its base, Amazon quickly expanded its offerings. And this became reflected in its online marketing using ads not only to highlight a product, service or site but also to get users "acquired" to get the most share from them. Isn't that the point of marketing?
Online marketing planning and measurement must be joined at the hip with business development strategies, not just a pretty add-on. This requires complex and agile marketing development and, critically, working with partners that offer a strong armory of technology solutions to support hard business goals.
To maximize customer acquisition and share, advertisers must work with marketing service partners to design strategies that deliver brand awareness, interaction and even e-commerce capabilities. Advertisers should establish measurement parameters and goals, ensuring that their partners use the sophisticated, learning-based technology solutions available to target, traffic, optimize and measure your campaign's performance. Demand that they deliver campaign analysis in real time.
Using these powerful technologies will enable marketers not only to measure the reach of their online marketing but, most importantly, they will allow the campaign to be intelligent and nimble. This means optimizing ads that are not performing creatively, placing them on sites at the right time and position for maximum effect, delivering results on the fly — and providing customer data to further enhance follow-up marketing.
The result? A better, smarter return on marketing dollars. All of a sudden, those click-throughs are not quite as appealing. Do yourself a favor and add more meaning to your measurement. You, and the boss, will be delighted with the ROI results.
American Express Sees Customer Shift to Web
NEW YORK — The Internet found a champion at the archly traditional National Retail Federation's 92nd Annual Convention…
Poll: Chinese Consumers Want More U.S. Products
A public opinion poll of China's emerging urban middle class found that high-quality personal care toiletries and consumer…
Coremetrics, Performics Team for Online Efforts
Coremetrics, a Web-based marketing analytics solution provider, and Performics, Chicago, an online marketing services company, said yesterday they…

redpajama_set_name: RedPajamaCommonCrawl


- Did you enjoy the AAF's debut? Do you have any reservations regarding the product?
- The Pistons are back in playoff contention. Does that make you bummed?
- Are you buying what the AAF is selling?
- Kareem Hunt is back in the NFL with Cleveland. Did the Browns make a mistake signing him?


Ever since its creation in 1967, Bravo's history has been built upon innovative products and successful ideas: Bravo introduced to the world the philosophy of Trittico, the multi-purpose machine that since 1974 has evolved into its current sixth generation edition.
K24 Evo with Magic Carpet: K24 Evo is the 24 kg continuous chocolate tempering machine. A cutting edge technology applied on the machine and on its accessories ensures perfect performances! It's equipped with preset programs, control of the temperature of the chocolate at its heart, anti-congealing lamps to heat the grid and to let chocolate flows bank in the tank, self-cleaning program to easily change the type/colour of the chocolate, programmable volumetric pedal dispenser, and many others advantages and features. It is equipped with inclined lateral sides which create a more efficient chocolate dripping.
The Magic Carpet is a coating belt for the complete or partial enrobing of the products.
Blast & Shock: a powerful blast chiller & shock freezer that assures you the perfect conservation of your sweet or savoury food production. Blast & Shock can freeze up to 6 pans (B&S5) or up to 36 pans (B&S14) of gelato or 5 to 28 trays.
G 20: an advanced professional batch-freezer for restaurants and coffee shops easy to use for the production of dry, soft, creamy, high quality gelato and ice cream.
Gelmatic M: high performance batch-freezer that allows to obtain results above market standards, thanks to the high freezing system technology, that takes advantage at most of the heat exchange for an optimal cooling and resulting freezing of gelato mixture.
Trittico M: the uniqueness of Trittico comes from its special structure: made of one upper vertical tank that heats and mixes the ingredients, and one lower horizontal tank that freezes the mixture for gelato or premium ice-cream.
Trittico Executive: it is the first multi-function machine for gelato, chocolate, pastries and catering. Thanks to its micro-processor, the machine automatically handles the cooking, cooling, and the emulsion of your recipes. Trittico Executive allows you to create also tempering with white chocolate, dark and milk chocolate.


Benz, Dominik ; Hotho, Andreas ; Jäschke, Robert ; Stumme, Gerd ; Halle, Axel ; Lima-Gerlach, Angela Sanches ; Steenweg, Helge ; Stefani, Sven: Academic Publication Management with PUMA - collect, organize and share publications. In: Proceedings of the 14. European Conference on Research and Advanced Technology for Digital Libraries , 2010, S. 417-420.


Vote 100: Celebrating Women Composers marks the centenary of women gaining the vote through democracy in action.
'Lead On' – by Lucy Pankhurst, a relative of leading suffragette Emmeline Pankhurst, features among music by a diverse range of women composers. Performances includes premieres of a recently rediscovered song by Alma Mahler and a trio written in 1915 by Morfydd Owen.
Musicians include Polina Shepherd, Rozanna Madylus and special guests including TableMusic, vocal/instrumental group HEARD Collective – Daisy Chute and Cerian, choir Women of Note, guitarist Brian Ashworth plus multi-pianist ensemble the Zongora Piano Group among others.
Featured composers include: Norah Blaney, Tracy Chapman, Rebecca Clarke, Litha Efthymiou, Lilian Elkington, Shena Fraser, Augusta Holmès, Cecilia McDowall, Thea Musgrave, Ruth Crawford Seeger, Laura Shur, Dame Ethel Smyth, Avril Coleridge-Taylor and Master of the Queen's Music Judith Weir.


text:
Protect your backlog with real-time updates
By Jared Fernley on 4/5/2019
Tags: mortgage options and process
As a builder, you can't afford to lose any of the deals in your backlog. That's why we created a digital process that helps get buyers approved, fast and hassle-free.
As one of the nations most trusted lenders, we work to ensure we do our part during the building process, so you don't miss closings.
Protect your backlog with extended lock products like Lock n' Build
Review your backlog with real-time updates on all your loans with Loan Status Monitor through Gateless
Applicant subject to credit and underwriting approval. Not all applicants will be approved for financing. Receipt of application does not represent an approval for financing or interest rate guarantee. Restrictions may apply, contact Guaranteed Rate for current rates and for more information. All information provided in this publication is for informational and educational purposes only, and in no way is any of the content contained herein to be construed as financial, investment, or legal advice or instruction. Guaranteed Rate, Inc. does not guarantee the quality, accuracy, completeness or timelines of the information in this publication. While efforts are made to verify the information provided, the information should not be assumed to be error free. Some information in the publication may have been provided by third parties and has not necessarily been verified by Guaranteed Rate, Inc. Guaranteed Rate, Inc. its affiliates and subsidiaries do not assume any liability for the information contained herein, be it direct, indirect, consequential, special, or exemplary, or other damages whatsoever and howsoever caused, arising out of or in connection with the use of this publication or in reliance on the information, including any personal or pecuniary loss, whether the action is in contract, tort (including negligence) or other tortious action. Guaranteed Rate does not provide tax advice. Please contact your tax adviser for any tax related questions.
Pay your mortgage
Guaranteed Rate Insurance
Ravenswood Title
Agent Advantage
Accessibility | Licensing | Notice to Vendors | Privacy Policies | SMS Terms | Terms of Use | NMLS Consumer Access
Delaware Licensed Loan Officers | Texas Consumers: How to file a complaint | Do not sell my personal information
Please note that applications, legal disclosures, documents or other material related to Guaranteed Rate products or services promoted on this page are offered in English only. The Spanish translation of this page is for convenience of our clients; however, not all pages are translated. If there is a discrepancy between the content of the translated page and the content of the same page in English, the English version will prevail.
© 2023 Guaranteed Rate, Inc. All rights reserved.
NMLS License #2611
3940 N. Ravenswood Chicago, IL 60613
The company name, Guaranteed Rate, should not suggest to a consumer that Guaranteed Rate provides an interest rate guaranteed prior to an interest lock.


text:
Inaugural 2020 Honourees
Tania Boler
Tania Boler, CEO, Elvie
No stranger to controversy, femtech brand Elvie regularly makes headlines with impactful campaigns and stunts designed to challenge taboos around women's health.
Its wireless breast pump was launched on the London Fashion Week catwalk, causing a stir that saw the product sell out in minutes. But, Elvie is best known for its issue-led campaigns.
In 2018, Londoners were stunned when giant inflatable boobs graced the capital's skyline, prompting public debate about the right of mothers to breastfeed in public without shame or embarrassment. Each one up to 6m tall, the boobs, in diverse shapes and skin tones - complete with stretch marks and nipple hair – went viral with the stunt's hashtag #FreetheFeed and reached millions via more than 100 press articles.
This year, Elvie's attention shifted onto stress incontinence – something that affects up to 1 in 3 women. When the brand's planned educational campaign for Edinburgh Fringe was banned for depicting images of vaginas, Elvie took a bold stand. Within just two weeks, Elvie commissioned an 18ft vagina blimp, defiantly flying it from a nearby sheep farm. A Change.org petition demanded that the council and Fringe #LetFannyFly, meanwhile social media and nationwide press drew millions of eyeballs via 218 articles and 8.4m social media impressions.
While Elvie's products are ground-breaking and empower women in their own right, the brand is more than just disruptive technology, it's part of a movement. And that movement is dedicated to challenging the status quo with frank conversation and education.
Copyright © 2021 Haymarket Events. All Rights Reserved.
Terms & Conditions | Privacy Policy | Website by Swipe Digital.


text:
Kogi Guber: Ebira monarch declares support for Gov Bello
The Ohinoyi Of Ebiraland, Dr Ado Ibrahim has thrown his weight behind Governor Yahaya Bello in his second term bid, saying that he has performed very well.
Ohinoyi made the call when he led the traditional rulers from the central Senatorial district of Kogi to pay Sallah homage to the governor at his residence on Monday in Okene.
Speaking on behalf of the traditional rulers, Ibrahim commended the governor's achievements for the past three years in his first term, stressing the need for the people to rally round him for his re-election for second term.
Ohinoyi, who also doubles as the Vice Chairman, Kogi State Traditional Council Of Chiefs, noted that the peace the state was currently enjoying today was not there during the previous administrations.
The royal father said Bello's first term was experimental period where there might be some unavoidable mistakes, but assured the people that in his second term he would right the wrong of the first term, and build on existing success.
The monarch, therefore, appealed to the people to rally round the governor for his second term bid, stressing that he deserved to be reelected.
In his remarks, the governor commended the monarchs for the unflinching support he had been receiving from them since his assumption of office three and half years ago, and urged them for continuous support.
Bello noted that the Ohinoyi remained the father of Ebiraland and as such the father of all, commanded high respect and influence in Kogi central and the state at large.
He urged other traditional rulers in the area to rally round the paramount ruler for peace, development and progress of the area and the state in general.
The governor urged the monarchs to unite and cooperate within themselves for peace and unity to thrive in the zone and in the state at large.
Ebira king Gov Bello	2019-08-13


text:
// Copyright 2013 Prometheus Team
// Licensed under the Apache License, Version 2.0 (the "License");
// you may not use this file except in compliance with the License.
// You may obtain a copy of the License at
//
// http://www.apache.org/licenses/LICENSE-2.0
//
// Unless required by applicable law or agreed to in writing, software
// distributed under the License is distributed on an "AS IS" BASIS,
// WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.
// See the License for the specific language governing permissions and
// limitations under the License.

package rules

import (
	"fmt"
	"path"
	"strings"
	"testing"
	"time"

	clientmodel "github.com/prometheus/client_golang/model"

	"github.com/prometheus/prometheus/rules/ast"
	"github.com/prometheus/prometheus/stats"
	"github.com/prometheus/prometheus/storage/metric/tiered"
	"github.com/prometheus/prometheus/utility/test"
)

var (
	testEvalTime = testStartTime.Add(testSampleInterval * 10)
	fixturesPath = "fixtures"
)

func annotateWithTime(lines []string, timestamp clientmodel.Timestamp) []string {
	annotatedLines := []string{}
	for _, line := range lines {
		annotatedLines = append(annotatedLines, fmt.Sprintf(line, timestamp))
	}
	return annotatedLines
}

func vectorComparisonString(expected []string, actual []string) string {
	separator := "\n--------------\n"
	return fmt.Sprintf("Expected:%v%v%v\nActual:%v%v%v ",
		separator,
		strings.Join(expected, "\n"),
		separator,
		separator,
		strings.Join(actual, "\n"),
		separator)
}

type testTieredStorageCloser struct {
	storage   *tiered.TieredStorage
	directory test.Closer
}

func (t testTieredStorageCloser) Close() {
	t.storage.Close()
	t.directory.Close()
}

// This is copied from storage/metric/helpers_test.go, which is unfortunate but
// presently required to make things work.
func NewTestTieredStorage(t test.Tester) (storage *tiered.TieredStorage, closer test.Closer) {
	var directory test.TemporaryDirectory
	directory = test.NewTemporaryDirectory("test_tiered_storage", t)
	storage, err := tiered.NewTieredStorage(2500, 1000, 5*time.Second, 0*time.Second, directory.Path())

	if err != nil {
		if storage != nil {
			storage.Close()
		}
		directory.Close()
		t.Fatalf("Error creating storage: %s", err)
	}

	if storage == nil {
		directory.Close()
		t.Fatalf("storage == nil")
	}
	started := make(chan bool)
	go storage.Serve(started)
	<-started
	closer = &testTieredStorageCloser{
		storage:   storage,
		directory: directory,
	}
	return
}

func newTestStorage(t test.Tester) (storage *tiered.TieredStorage, closer test.Closer) {
	storage, closer = NewTestTieredStorage(t)
	if storage == nil {
		t.Fatal("storage == nil")
	}
	storeMatrix(storage, testMatrix)
	return
}

func TestExpressions(t *testing.T) {
	// Labels in expected output need to be alphabetically sorted.
	var expressionTests = []struct {
		expr           string
		output         []string
		shouldFail     bool
		checkOrder     bool
		fullRanges     int
		intervalRanges int
	}{
		{
			expr:           `SUM(http_requests)`,
			output:         []string{`http_requests => 3600 @[%v]`},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests{instance="0"}) BY(job)`,
			output: []string{
				`http_requests{job="api-server"} => 400 @[%v]`,
				`http_requests{job="app-server"} => 1200 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 4,
		}, {
			expr: `SUM(http_requests{instance="0"}) BY(job) KEEPING_EXTRA`,
			output: []string{
				`http_requests{instance="0", job="api-server"} => 400 @[%v]`,
				`http_requests{instance="0", job="app-server"} => 1200 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 4,
		}, {
			expr: `SUM(http_requests) BY (job)`,
			output: []string{
				`http_requests{job="api-server"} => 1000 @[%v]`,
				`http_requests{job="app-server"} => 2600 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			// Non-existent labels mentioned in BY-clauses shouldn't propagate to output.
			expr: `SUM(http_requests) BY (job, nonexistent)`,
			output: []string{
				`http_requests{job="api-server"} => 1000 @[%v]`,
				`http_requests{job="app-server"} => 2600 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `
				// Test comment.
				SUM(http_requests) BY /* comments shouldn't
				have any effect */ (job) // another comment`,
			output: []string{
				`http_requests{job="api-server"} => 1000 @[%v]`,
				`http_requests{job="app-server"} => 2600 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `COUNT(http_requests) BY (job)`,
			output: []string{
				`http_requests{job="api-server"} => 4 @[%v]`,
				`http_requests{job="app-server"} => 4 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests) BY (job, group)`,
			output: []string{
				`http_requests{group="canary", job="api-server"} => 700 @[%v]`,
				`http_requests{group="canary", job="app-server"} => 1500 @[%v]`,
				`http_requests{group="production", job="api-server"} => 300 @[%v]`,
				`http_requests{group="production", job="app-server"} => 1100 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `AVG(http_requests) BY (job)`,
			output: []string{
				`http_requests{job="api-server"} => 250 @[%v]`,
				`http_requests{job="app-server"} => 650 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `MIN(http_requests) BY (job)`,
			output: []string{
				`http_requests{job="api-server"} => 100 @[%v]`,
				`http_requests{job="app-server"} => 500 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `MAX(http_requests) BY (job)`,
			output: []string{
				`http_requests{job="api-server"} => 400 @[%v]`,
				`http_requests{job="app-server"} => 800 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests) BY (job) - COUNT(http_requests) BY (job)`,
			output: []string{
				`http_requests{job="api-server"} => 996 @[%v]`,
				`http_requests{job="app-server"} => 2596 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `2 - SUM(http_requests) BY (job)`,
			output: []string{
				`http_requests{job="api-server"} => -998 @[%v]`,
				`http_requests{job="app-server"} => -2598 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `1000 / SUM(http_requests) BY (job)`,
			output: []string{
				`http_requests{job="api-server"} => 1 @[%v]`,
				`http_requests{job="app-server"} => 0.38461538461538464 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests) BY (job) - 2`,
			output: []string{
				`http_requests{job="api-server"} => 998 @[%v]`,
				`http_requests{job="app-server"} => 2598 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests) BY (job) % 3`,
			output: []string{
				`http_requests{job="api-server"} => 1 @[%v]`,
				`http_requests{job="app-server"} => 2 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests) BY (job) / 0`,
			output: []string{
				`http_requests{job="api-server"} => +Inf @[%v]`,
				`http_requests{job="app-server"} => +Inf @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests) BY (job) > 1000`,
			output: []string{
				`http_requests{job="app-server"} => 2600 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `1000 < SUM(http_requests) BY (job)`,
			output: []string{
				`http_requests{job="app-server"} => 1000 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests) BY (job) <= 1000`,
			output: []string{
				`http_requests{job="api-server"} => 1000 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests) BY (job) != 1000`,
			output: []string{
				`http_requests{job="app-server"} => 2600 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests) BY (job) == 1000`,
			output: []string{
				`http_requests{job="api-server"} => 1000 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `SUM(http_requests) BY (job) + SUM(http_requests) BY (job)`,
			output: []string{
				`http_requests{job="api-server"} => 2000 @[%v]`,
				`http_requests{job="app-server"} => 5200 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `http_requests{job="api-server", group="canary"}`,
			output: []string{
				`http_requests{group="canary", instance="0", job="api-server"} => 300 @[%v]`,
				`http_requests{group="canary", instance="1", job="api-server"} => 400 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 2,
		}, {
			expr: `http_requests{job="api-server", group="canary"} + delta(http_requests{job="api-server"}[5m], 1)`,
			output: []string{
				`http_requests{group="canary", instance="0", job="api-server"} => 330 @[%v]`,
				`http_requests{group="canary", instance="1", job="api-server"} => 440 @[%v]`,
			},
			fullRanges:     4,
			intervalRanges: 0,
		}, {
			expr: `delta(http_requests[25m], 1)`,
			output: []string{
				`http_requests{group="canary", instance="0", job="api-server"} => 150 @[%v]`,
				`http_requests{group="canary", instance="0", job="app-server"} => 350 @[%v]`,
				`http_requests{group="canary", instance="1", job="api-server"} => 200 @[%v]`,
				`http_requests{group="canary", instance="1", job="app-server"} => 400 @[%v]`,
				`http_requests{group="production", instance="0", job="api-server"} => 50 @[%v]`,
				`http_requests{group="production", instance="0", job="app-server"} => 250 @[%v]`,
				`http_requests{group="production", instance="1", job="api-server"} => 100 @[%v]`,
				`http_requests{group="production", instance="1", job="app-server"} => 300 @[%v]`,
			},
			fullRanges:     8,
			intervalRanges: 0,
		}, {
			expr: `sort(http_requests)`,
			output: []string{
				`http_requests{group="production", instance="0", job="api-server"} => 100 @[%v]`,
				`http_requests{group="production", instance="1", job="api-server"} => 200 @[%v]`,
				`http_requests{group="canary", instance="0", job="api-server"} => 300 @[%v]`,
				`http_requests{group="canary", instance="1", job="api-server"} => 400 @[%v]`,
				`http_requests{group="production", instance="0", job="app-server"} => 500 @[%v]`,
				`http_requests{group="production", instance="1", job="app-server"} => 600 @[%v]`,
				`http_requests{group="canary", instance="0", job="app-server"} => 700 @[%v]`,
				`http_requests{group="canary", instance="1", job="app-server"} => 800 @[%v]`,
			},
			checkOrder:     true,
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			expr: `sort_desc(http_requests)`,
			output: []string{
				`http_requests{group="canary", instance="1", job="app-server"} => 800 @[%v]`,
				`http_requests{group="canary", instance="0", job="app-server"} => 700 @[%v]`,
				`http_requests{group="production", instance="1", job="app-server"} => 600 @[%v]`,
				`http_requests{group="production", instance="0", job="app-server"} => 500 @[%v]`,
				`http_requests{group="canary", instance="1", job="api-server"} => 400 @[%v]`,
				`http_requests{group="canary", instance="0", job="api-server"} => 300 @[%v]`,
				`http_requests{group="production", instance="1", job="api-server"} => 200 @[%v]`,
				`http_requests{group="production", instance="0", job="api-server"} => 100 @[%v]`,
			},
			checkOrder:     true,
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			// Single-letter label names and values.
			expr: `x{y="testvalue"}`,
			output: []string{
				`x{y="testvalue"} => 100 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 1,
		}, {
			// Lower-cased aggregation operators should work too.
			expr: `sum(http_requests) by (job) + min(http_requests) by (job) + max(http_requests) by (job) + avg(http_requests) by (job)`,
			output: []string{
				`http_requests{job="app-server"} => 4550 @[%v]`,
				`http_requests{job="api-server"} => 1750 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			// Deltas should be adjusted for target interval vs. samples under target interval.
			expr:           `delta(http_requests{group="canary", instance="1", job="app-server"}[18m], 1)`,
			output:         []string{`http_requests{group="canary", instance="1", job="app-server"} => 288 @[%v]`},
			fullRanges:     1,
			intervalRanges: 0,
		}, {
			// Rates should transform per-interval deltas to per-second rates.
			expr:           `rate(http_requests{group="canary", instance="1", job="app-server"}[10m])`,
			output:         []string{`http_requests{group="canary", instance="1", job="app-server"} => 0.26666666666666666 @[%v]`},
			fullRanges:     1,
			intervalRanges: 0,
		}, {
			// Counter resets in middle of range are ignored by delta() if counter == 1.
			expr:           `delta(testcounter_reset_middle[50m], 1)`,
			output:         []string{`testcounter_reset_middle => 90 @[%v]`},
			fullRanges:     1,
			intervalRanges: 0,
		}, {
			// Counter resets in middle of range are not ignored by delta() if counter == 0.
			expr:           `delta(testcounter_reset_middle[50m], 0)`,
			output:         []string{`testcounter_reset_middle => 50 @[%v]`},
			fullRanges:     1,
			intervalRanges: 0,
		}, {
			// Counter resets at end of range are ignored by delta() if counter == 1.
			expr:           `delta(testcounter_reset_end[5m], 1)`,
			output:         []string{`testcounter_reset_end => 0 @[%v]`},
			fullRanges:     1,
			intervalRanges: 0,
		}, {
			// Counter resets at end of range are not ignored by delta() if counter == 0.
			expr:           `delta(testcounter_reset_end[5m], 0)`,
			output:         []string{`testcounter_reset_end => -90 @[%v]`},
			fullRanges:     1,
			intervalRanges: 0,
		}, {
			// count_scalar for a non-empty vector should return scalar element count.
			expr:           `count_scalar(http_requests)`,
			output:         []string{`scalar: 8 @[%v]`},
			fullRanges:     0,
			intervalRanges: 8,
		}, {
			// count_scalar for an empty vector should return scalar 0.
			expr:           `count_scalar(nonexistent)`,
			output:         []string{`scalar: 0 @[%v]`},
			fullRanges:     0,
			intervalRanges: 0,
		}, {
			// Empty expressions shouldn"t parse.
			expr:       ``,
			shouldFail: true,
		}, {
			// Interval durations can"t be in quotes.
			expr:       `http_requests["1m"]`,
			shouldFail: true,
		}, {
			// Binop arguments need to be scalar or vector.
			expr:       `http_requests - http_requests[1m]`,
			shouldFail: true,
		}, {
			expr: `http_requests{group!="canary"}`,
			output: []string{
				`http_requests{group="production", instance="1", job="app-server"} => 600 @[%v]`,
				`http_requests{group="production", instance="0", job="app-server"} => 500 @[%v]`,
				`http_requests{group="production", instance="1", job="api-server"} => 200 @[%v]`,
				`http_requests{group="production", instance="0", job="api-server"} => 100 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 4,
		}, {
			expr: `http_requests{job=~"server",group!="canary"}`,
			output: []string{
				`http_requests{group="production", instance="1", job="app-server"} => 600 @[%v]`,
				`http_requests{group="production", instance="0", job="app-server"} => 500 @[%v]`,
				`http_requests{group="production", instance="1", job="api-server"} => 200 @[%v]`,
				`http_requests{group="production", instance="0", job="api-server"} => 100 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 4,
		}, {
			expr: `http_requests{job!~"api",group!="canary"}`,
			output: []string{
				`http_requests{group="production", instance="1", job="app-server"} => 600 @[%v]`,
				`http_requests{group="production", instance="0", job="app-server"} => 500 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 2,
		}, {
			expr:           `count_scalar(http_requests{job=~"^server$"})`,
			output:         []string{`scalar: 0 @[%v]`},
			fullRanges:     0,
			intervalRanges: 0,
		}, {
			expr: `http_requests{group="production",job=~"^api"}`,
			output: []string{
				`http_requests{group="production", instance="1", job="api-server"} => 200 @[%v]`,
				`http_requests{group="production", instance="0", job="api-server"} => 100 @[%v]`,
			},
			fullRanges:     0,
			intervalRanges: 2,
		},
	}

	tieredStorage, closer := newTestStorage(t)
	defer closer.Close()
	tieredStorage.Flush()

	for i, exprTest := range expressionTests {
		expectedLines := annotateWithTime(exprTest.output, testEvalTime)

		testExpr, err := LoadExprFromString(exprTest.expr)

		if err != nil {
			if exprTest.shouldFail {
				continue
			}
			t.Errorf("%d. Error during parsing: %v", i, err)
			t.Errorf("%d. Expression: %v", i, exprTest.expr)
		} else {
			if exprTest.shouldFail {
				t.Errorf("%d. Test should fail, but didn't", i)
			}
			failed := false
			resultStr := ast.EvalToString(testExpr, testEvalTime, ast.TEXT, tieredStorage, stats.NewTimerGroup())
			resultLines := strings.Split(resultStr, "\n")

			if len(exprTest.output) != len(resultLines) {
				t.Errorf("%d. Number of samples in expected and actual output don't match", i)
				failed = true
			}

			if exprTest.checkOrder {
				for j, expectedSample := range expectedLines {
					if resultLines[j] != expectedSample {
						t.Errorf("%d.%d. Expected sample '%v', got '%v'", i, j, resultLines[j], expectedSample)
						failed = true
					}
				}
			} else {
				for j, expectedSample := range expectedLines {
					found := false
					for _, actualSample := range resultLines {
						if actualSample == expectedSample {
							found = true
						}
					}
					if !found {
						t.Errorf("%d.%d. Couldn't find expected sample in output: '%v'", i, j, expectedSample)
						failed = true
					}
				}
			}

			analyzer := ast.NewQueryAnalyzer(tieredStorage)
			analyzer.AnalyzeQueries(testExpr)
			if exprTest.fullRanges != len(analyzer.FullRanges) {
				t.Errorf("%d. Count of full ranges didn't match: %v vs %v", i, exprTest.fullRanges, len(analyzer.FullRanges))
				failed = true
			}
			if exprTest.intervalRanges != len(analyzer.IntervalRanges) {
				t.Errorf("%d. Count of interval ranges didn't match: %v vs %v", i, exprTest.intervalRanges, len(analyzer.IntervalRanges))
				failed = true
			}

			if failed {
				t.Errorf("%d. Expression: %v\n%v", i, exprTest.expr, vectorComparisonString(expectedLines, resultLines))
			}
		}
	}
}

var ruleTests = []struct {
	inputFile         string
	shouldFail        bool
	errContains       string
	numRecordingRules int
	numAlertingRules  int
}{
	{
		inputFile:         "empty.rules",
		numRecordingRules: 0,
		numAlertingRules:  0,
	}, {
		inputFile:         "mixed.rules",
		numRecordingRules: 2,
		numAlertingRules:  2,
	},
	{
		inputFile:   "syntax_error.rules",
		shouldFail:  true,
		errContains: "Error parsing rules at line 5",
	},
	{
		inputFile:   "non_vector.rules",
		shouldFail:  true,
		errContains: "does not evaluate to vector type",
	},
}

func TestRules(t *testing.T) {
	for i, ruleTest := range ruleTests {
		testRules, err := LoadRulesFromFile(path.Join(fixturesPath, ruleTest.inputFile))

		if err != nil {
			if !ruleTest.shouldFail {
				t.Fatalf("%d. Error parsing rules file %v: %v", i, ruleTest.inputFile, err)
			} else {
				if !strings.Contains(err.Error(), ruleTest.errContains) {
					t.Fatalf("%d. Expected error containing '%v', got: %v", i, ruleTest.errContains, err)
				}
			}
		} else {
			numRecordingRules := 0
			numAlertingRules := 0

			for j, rule := range testRules {
				switch rule.(type) {
				case *RecordingRule:
					numRecordingRules++
				case *AlertingRule:
					numAlertingRules++
				default:
					t.Fatalf("%d.%d. Unknown rule type!", i, j)
				}
			}

			if numRecordingRules != ruleTest.numRecordingRules {
				t.Fatalf("%d. Expected %d recording rules, got %d", i, ruleTest.numRecordingRules, numRecordingRules)
			}
			if numAlertingRules != ruleTest.numAlertingRules {
				t.Fatalf("%d. Expected %d alerting rules, got %d", i, ruleTest.numAlertingRules, numAlertingRules)
			}

			// TODO(julius): add more complex checks on the parsed rules here.
		}
	}
}

func TestAlertingRule(t *testing.T) {
	// Labels in expected output need to be alphabetically sorted.
	var evalOutputs = [][]string{
		{
			`ALERTS{alertname="HttpRequestRateLow", alertstate="pending", group="canary", instance="0", job="app-server", severity="critical"} => 1 @[%v]`,
			`ALERTS{alertname="HttpRequestRateLow", alertstate="pending", group="canary", instance="1", job="app-server", severity="critical"} => 1 @[%v]`,
		},
		{
			`ALERTS{alertname="HttpRequestRateLow", alertstate="pending", group="canary", instance="0", job="app-server", severity="critical"} => 0 @[%v]`,
			`ALERTS{alertname="HttpRequestRateLow", alertstate="firing", group="canary", instance="0", job="app-server", severity="critical"} => 1 @[%v]`,
			`ALERTS{alertname="HttpRequestRateLow", alertstate="pending", group="canary", instance="1", job="app-server", severity="critical"} => 0 @[%v]`,
			`ALERTS{alertname="HttpRequestRateLow", alertstate="firing", group="canary", instance="1", job="app-server", severity="critical"} => 1 @[%v]`,
		},
		{
			`ALERTS{alertname="HttpRequestRateLow", alertstate="firing", group="canary", instance="1", job="app-server", severity="critical"} => 0 @[%v]`,
			`ALERTS{alertname="HttpRequestRateLow", alertstate="firing", group="canary", instance="0", job="app-server", severity="critical"} => 0 @[%v]`,
		},
		{
		/* empty */
		},
		{
		/* empty */
		},
	}

	tieredStorage, closer := newTestStorage(t)
	defer closer.Close()
	tieredStorage.Flush()

	alertExpr, err := LoadExprFromString(`http_requests{group="canary", job="app-server"} < 100`)
	if err != nil {
		t.Fatalf("Unable to parse alert expression: %s", err)
	}
	alertName := "HttpRequestRateLow"
	alertLabels := clientmodel.LabelSet{
		"severity": "critical",
	}
	rule := NewAlertingRule(alertName, alertExpr.(ast.VectorNode), time.Minute, alertLabels, "summary", "description")

	for i, expected := range evalOutputs {
		evalTime := testStartTime.Add(testSampleInterval * time.Duration(i))
		actual, err := rule.Eval(evalTime, tieredStorage)
		if err != nil {
			t.Fatalf("Error during alerting rule evaluation: %s", err)
		}
		actualLines := strings.Split(actual.String(), "\n")
		expectedLines := annotateWithTime(expected, evalTime)
		if actualLines[0] == "" {
			actualLines = []string{}
		}

		failed := false
		if len(actualLines) != len(expectedLines) {
			t.Errorf("%d. Number of samples in expected and actual output don't match (%d vs. %d)", i, len(expectedLines), len(actualLines))
			failed = true
		}

		for j, expectedSample := range expectedLines {
			found := false
			for _, actualSample := range actualLines {
				if actualSample == expectedSample {
					found = true
				}
			}
			if !found {
				t.Errorf("%d.%d. Couldn't find expected sample in output: '%v'", i, j, expectedSample)
				failed = true
			}
		}

		if failed {
			t.Fatalf("%d. Expected and actual outputs don't match:\n%v", i, vectorComparisonString(expectedLines, actualLines))
		}
	}
}

redpajama_set_name: RedPajamaGithub


We have a wide range of drill pipe screens including bar/rod drill pipe screens, slotted tube drill pipe screens, appropriate outer rings for each type, and perforated retrievable as well as nonretrievable drill pipe screens as per your requirement. we can customize design of drill pipe screens, parts and accessories to your exact specifications.
Drill Pipe Screens are used in directional drilling application.
Drill Pipe Screens are used to protect MWD Tools of oilfield drilling operations including many different lengths and types of drill pipe screens for the protection of your expensive and sensitive measurement while drilling equipment.


Adaptiiv Medical Technologies Inc. is the only company in the world to receive U.S. FDA 510(k) clearance to market its 3D printing software for use in radiation oncology. Adaptiiv's software integrates with existing radiation treatment processes to design patient-specific accessories. In 2018, the company signed a global distribution agreement with CIVCO Radiotherapy, a leading global provider of innovative, patient-centric solutions in radiotherapy. These developments uniquely position Adaptiiv to support the growth of personalized medicine with its simple and intuitive technology while providing a clear, tangible ROI to its customers. Adaptiiv is generating revenue from customers in seven countries.
AmacaThera was founded with the aim of developing a drug delivery platform to provide sustained drug release over several days from a single injection. The first product targets superior post-operative pain control with the goal of reducing the need for opioids following surgery. AmacaThera has recently closed a seed financing that will be used to advance the technology through to the end of a Phase I clinical trial.
ChipCare is a disruptive company developing one of the most versatile point-of-care (POC) diagnostic platforms in the world. What differentiates ChipCare is the 3-in-1 capability to perform nucleic acid, immunoassay and cell tests using disposable cartridges on the same analyzer. ChipCare is targeting the >230,000 US physician labs, pharmacies and specialty clinics in the >US$3 billion women's health & STI market that currently has no molecular POC platform available. ChipCare will lead with a Chlamydia / Gonorrhea / Trichomoniasis nucleic acid test – the most reported notifiable diseases in the US, which are actively screened and 100% reimbursed by US payors.
Conavi Medical is a revenue-generating medical device company that develops image guidance technologies for use in minimally invasive cardiovascular procedures. Conavi's first commercialized product, the Novasight Hybrid system is the first coronary imaging system to combine simultaneous, co-registered intravascular ultrasound and optical coherence tomography. Their second technology is the Foresight ICE system, which is the first intracardiac echocardiography system capable of imaging 360 degrees around the circumference of the catheter in side and forward-viewing modes, and rendering 3D images. Both technologies have received FDA clearance and have been used in clinical procedures. The company also has distribution agreements with large, publicly-traded companies in Japan and China. Conavi is raising late-stage financing to fund scale-up of sales and manufacturing.
Curiato is a clinical stage company that has developed a real-time skin monitoring and data platform to help make healthcare safer and more efficient. Curiato provides care staff with objective skin data to help identify expensive and painful skin related illnesses such as bedsores. No such means exists to monitor the skin, the largest organ on the human body and the first line of defense. This presents a huge opportunity as skin breakdown in the elderly is associated with a host of adverse events including wounds and infections. With an aging population and a projected nursing shortage, new technologies that can monitor & help prevent skin breakdown is more important than ever.
Enhanced Medical Nutrition ("EMN") is a life sciences organization engaged in the research, development, and distribution of evidence-based clinical nutrition. EMN supports the patient's journey through surgery with clinical nutrition to help patients prepare better and recover faster. EMN's initial offerings include two evidence-based enteral formulas (drinks/tube feeds) to support muscle metabolism, immune function and accelerate recovery.
EBT Medical is developing SaphStim, a clinical-grade, discreet, non-invasive neurostimulator and associated eco-system for the dramatically underserved Overactive Bladder (OAB) market. When used for just 30 minutes 2x / week, SaphStim delivers prescription strength efficacy with minimal to no side effects. SaphStim will become the default 1st line therapy of choice for patients and physicians, disrupting and expanding the existing $4B market while restoring control, dignity, and independence to those silently suffering from OAB. EBT is currently raising a seed round to fund additional clinical and product development work.
Empirica Therapeutics is a pre-clinical company developing candidates against the most aggressive forms of cancer, including glioblastoma and brain metastases. The first product in their pipeline is a CD133-specific CAR-T directed against brain cancer stem cells which may also have utility for patients with other treatment-refractory cancers that express CD133. The company aims to identify additional novel targets that can broaden applications in brain tumours and other cancers, using a platform that enables the creation of multiple modalities of treatments. Empirica is raising seed financing to fund pre-clinical development.
Epineuron is a development-stage medical device company creating the world's first adjunctive bioelectronic therapy used to treat injured peripheral nerves and accelerate their regeneration providing both greater and earlier functional recovery after injury. There are currently no drugs or devices that can provide patients a more meaningful recovery above the standard of care which is surgery. The company has recently received a Breakthrough Device Designation from the FDA making them one of the first Canadian companies ever to receive this designation. Epineuron has a unique opportunity to expedite market access of its technology and capture the US market. The company is raising seed financing to complete product development and perform first-in-human studies using their novel technology.
ImmunoBiochem, is developing novel biologics that target unique proteins which are selectively amplified in the tumor microenvironment, aiming to overcome high tumor heterogeneity and associated poor responses and resistance to targeted therapies. ImmunoBiochem's lead molecule, IMB-212, is a potentiated antibody acting on a tumor target that is amplified in the secretome of cancer cells. IMB-212 is in development for triple-negative breast cancer (TNBC) and other solid tumor indications. ImmunoBiochem is currently raising a Series A round to advance the lead molecule into the clinic, targeting a close in early 2019.
iTP Biomedica uses its proprietary big data bioinformatics platform to develop accurate prognostic tests for oncology and other complex diseases. They have a fully-developed BladderPredict® to address the underserved bladder cancer prognosis market and is ready for marketing with a strategic partner. As part of their pipeline iTP also has a powerful prognostic test in development for chronic kidney disease progression. The company is seeking seed financing to conclude a physician experience program for BladderPredict® and advance their cancer prognosis pipeline.
KisoJi is a biotechnology company focused on creating best-in-class drugs based on its novel screening platforms in antibodies, stem cells and cancer stem cells. Through this platform, KisoJi will create next generation antibodies that have unique anti-cancer mechanisms. Such therapeutic antibodies have the potential to treat a wide range of cancers. KisoJi is led by a successful and experienced senior management team with extensive drug discovery and clinical translation expertise.
ManagingLife tackles the chronic pain and opioid crises through their app-based pain management platform. It is the most comprehensive digital solution for managing pain on the market combining self-management, improved measurement, and remote monitoring. Used by over 33,000 people from 130 countries, ManagingLife's platform is deployed at five hospitals and is undergoing a fully-funded multi-site validation study led by Canada's largest academic hospital, the University Health Network. ManagingLife licenses its platform to health plans and disability carriers, including Green Shield Canada and RBC Insurance, who collectively have 4.5 million individuals under coverage. ManagingLife is raising seed financing to pursue their US-based pipeline and continue momentum.
Marion Surgical is a revenue-generating company that provides virtual reality surgical simulators to train residents. Their advanced sensor technology records, analyses, and provides haptic feedback for the exact movements of surgeons and instruments in a multi-user, globally connected VR network. Marion is raising Series A financing to expand simulated procedures and ramp up sales.
Matrizyme Pharma Corporation is a clinical-stage company that has developed an innovative therapy, a proprietary collagenase enzyme formulation – MZ-004, to facilitate angioplasty in patients suffering from Chronic Total Occlusions (CTOs). CTOs are complete blockages of an artery and represent a significant, under-served market due to their complexity and high rate of treatment failure. Matrizyme is raising Series B financing for a pivotal registration trial with its CTO System, comprised of MZ-004 and a soft-tipped guidewire designated as a Device/Biologic Combination Product by the FDA.
Mediphage Bioceuticals is a pre-clinical stage company that is developing safe, effective and accessible gene delivery platforms to unlock the therapeutic power of personalized, redoseable genetic medicine. They have developed a novel transgene delivery system, ministring DNA, for the delivery of genes into cells for gene therapies, cell engineering, and gene editing. After completing the Illumina Accelerator Program in 2018, Mediphage Bioceuticals is seeking seed financing for the commercialization of ministring DNA.
MediSeen is a leading HIPAA/PHIPA-compliant, software platform that enables health care partners to seamlessly manage patient care in home. MediSeen provides patients with a convenient alternative to visiting overwhelmed health care facilities, delivering better access to care. Providers can set their profile, schedule and area of coverage. In turn, patients simply browse providers and choose their provider preference, time and location that works for them. MediSeen has an experienced founding team that includes serial entrepreneurs with successful exits and is currently raising Series A financing to expand their userbase.
MIMOSA Diagnostics is a clinical-stage mobile health platform leveraging AI for the prevention and surveillance of diabetic foot wounds. Their device is designed for physicians, and also for patients to utilize in their own homes as a remote sensing tool for tissue health as regular inspection is the key to wound and amputation prevention. MIMOSA is raising a Series A round to support 510K approval and commercialization.
Northern Therapeutics Inc. is a clinical biopharmaceutical company developing novel cell & gene therapies for pulmonary disorders. Their lead therapeutic targets pulmonary arterial hypertension – an incurable disease associated with widespread loss of pulmonary microvasculature, leading to increased pulmonary vascular resistance. Northern Therapeutics has pioneered an angiogenic cell and gene therapy designed to promote repair and regenerate lung microcirculation, representing a first-in-class technology entering Phase 2 trials. The company is also developing the next generation of mesenchymal stem cell therapy for chronic and acute indications. Northern Therapeutics is raising Series A financing to continue clinical trials and pipeline development.
Ovensa is a pre-clinical stage company that capitalizes on its proprietary TRIOZAN™ Nanomedicine Delivery Platform to solve barrier crossing, intracellular uptake and therapeutic resistance challenges in complex diseases. The company focuses on oncology, immuno-oncology and neurodegenerative diseases. Ovensa is raising Series A financing to fund clinical trials in recurrent glioblastoma.
Phenomic AI is a revenue-generating company that is building a platform to identify and evolve antibodies towards phenotypic effects defined by computer vision. The company's algorithm analyzes both microscopy imaging and chemical data to screen lead drug candidates with an initial focus on idiopathic pulmonary fibrosis. Phenomic is seeking introductions prior to raising Series A financing to continue product development and expand its team.
ProteinQure is a revenue-generating software platform for computational peptide drug discovery. ProteinQure combines quantum computing, molecular simulations, and machine learning to enable the structure-based design of drugs. These physics-based methods make the process less dependent on large data sets, enabling the modeling of complicated disease targets & protein dynamics. The company recently started their first multi-year collaboration with MedImmune – a first for quantum computing startups worldwide. ProteinQure has also synthesized their first novel peptides through a CRO and have performed experimental characterizations with exciting results. The company is raising seed financing to deliver on three drug discovery partnerships.
Rna Diagnostics is a clinical stage biotechnology company developing a unique test, RDA, to tell doctors, very early in cancer therapy, whether the therapy is working or not. Doctors can use this information to avoid treating patients with expensive, toxic drugs, and instead switch to the next best alternative. The company has initiated a 2-year, prospective multi-national pivotal clinical trial (BREVITY) to prove the clinical validity and utility of RDA. After raising a Series A round in 2018, Rna Diagnostics will be seeking Series B financing following BREVITY.
Satellos is a pre-clinical platform company focused on stimulating the body's innate tissue repair and regeneration mechanisms using biologic and small molecule drugs with an initial focus on muscle regeneration, a field in which Dr. Rudnicki – their CSO, is a world leader. Satellos has discovered a novel means to modulate the balance between stem cell replenishment and differentiation by targeting polarity. Acute injury or trauma, chronic illness or genetic diseases, and aging lead to alterations in stem cell polarity which will make it possible to enhance tissue regeneration for the treatment of a wide range of diseases through drug interventions. Satellos is pursuing a $15M Series A financing.
Sernova Corp. (TSX-V: SVA) is a clinical-stage company developing regenerative medicine therapeutics technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life for people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.
Steadiwear has created a lightweight and non-powered glove, the Steadi-One, designed to significantly reduce hand tremors in Essential Tremor and Parkinson's Disease. Their assistive device allows patients to improve independence while drastically reducing ongoing healthcare costs. With Steadiwear's patent protected, prototyped, and beta tested technology, they are raising a bridge round prior to their Series A for a full North American product launch.
Supports Health is a digital therapeutic company revolutionizing mental healthcare through their best-in-class eDBT app, Resili. The company's initial focus is on family caregivers to provide psychoeducation, digital therapeutics, and peer support through a monthly subscription. Their app will also be available institutionally to hospitals, care centres, family health practitioners, universities, and insurers. Supports Health is raising seed funding to further expand their userbase.
ToeFx is a pre-clinical-stage medical device company that has developed a cost-effective, non-invasive technology for treatment of the common and persistent toenail fungal infection. Fungal infection of nails is among the most prevalent infectious diseases in humans (affecting 10-20% of the population). The global toenail fungus therapeutics market was valued at US$ 3.1 billion in 2015 and is expected to show a compound annual growth rate of 9.2% until 2021. When used for just 15 minutes every 3 weeks, for a total of 4-6 treatments, ToeFx's solution delivers 90% efficacy with no side effect. ToeFx is currently raising investment to fund clinical testing, U.S. FDA 510(k) clearance, and a sales/marketing team.
Tracery Ophthalmics is a clinical stage health tech & ophthalmic imaging company leveraging artificial intelligence for precision drug development with an initial focus on blinding eye diseases. Tracery's platform leverages advanced computing to facilitate efficiencies of clinical trials by identifying the correct participants. Functions are integrated through the cloud and will efficiently provide data, information, and answers as a service to patients, biotech, and pharma – accelerating precision drug development for AMD. Tracery placed first in Johnson & Johnson's AI for Drug Development competition and is currently raising a seed round to further grow their ring of expert users.
Triumvira Immunologics is an immunotherapy company developing novel T cell therapies that are safer and more efficacious than current cancer treatments. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients. Triumvira is raising Series A financing to commence phase I trials.
Vena Medical is a clinical-stage device company that has created a forward viewing imaging microcatheter to provide a real-time navigational perspective for interventional physicians. Open surgeries are rapidly being replaced by minimally invasive procedures which has yet to take place inside patients veins and arteries thus allowing the Vena Microcatheter to lead the way. Vena will be raising Series A financing to submit regulatory approvals and continue validation studies.
The genesis of VoxNeuro is a scientific breakthrough in the quantitative measurement and assessment of concussions by Dr. John F. Connolly, world-renowned neuroscientist at McMaster University in Canada. Our patented protocol and proprietary algorithms are the backbone of the first and only clinically available assessment in the world that informs and accelerates cognitive rehabilitation by identifying specific areas of cognitive function impacted by an injury.
7D Surgical is a commercial-stage medical technology company developing advanced optical technologies and machine vision-based registration algorithms to improve surgical workflow and patient care. 7D Surgical's flagship Machine-vision Image Guidance System (MvIGS) delivers profound improvement to surgical workflows in spine and cranial navigation in surgeries. Their modules have FDA 510(k) clearance and Health Canada MDL approval for spinal and cranial navigation. 7D Surgical is currently raising financing to scale commercialization and expand their product pipeline.


text:
Regulation of monocyte/macrophage function by adenosine receptors
G. Haskó, Csaba Szabó
Adenosine is an endogenous purine nucleoside that, subsequent to its release from cells or after being generated extracellularly, diffuses to the membrane of surrounding cells, in which it binds to specific cell surface structures that recognize it, termed adenosine receptors. There are four types of adenosine receptors, all of which are members of the G-protein-coupled family of receptors. They are the A1, A2A, A2B, and A3 adenosine receptors. 1-4 Although adenosine is present at low concentrations in the extracellular space, metabolically stressful conditions increase its extracellular levels dramatically. Adenosine receptors are expressed abundantly on cells of the monocyte/macrophage lineage, and through these receptors adenosine exerts substantial modulatory effects on monocyte/macrophage function. 5-7 Because macrophages are activated by stressful stimuli such as inflammation, hypoxia, and ischemia, the same stimuli that can result in accumulation of extracellular adenosine, adenosine receptors expressed on macrophages represent a sensor system providing macrophages with essential information about the inflammatory or ischemic environment. 6 This mechanism allows macrophages to fine-tune their responses to stressful stimuli. In this chapter, we focus on the consequences of adenosine receptor engagement on monocyte and macrophage function. We will delineate the effect of stimulating the various adenosine receptor subtypes on macrophage differentiation/proliferation, phagocytosis, membrane protein expression, and mediator production. A more complete understanding of the regulation of monocyte/macrophage function by adenosine receptor engagement should help develop novel therapeutic ways of manipulating disorders that are associated with exuberant or insufficient macrophage activation.
Adenosine Receptors
Therapeutic Aspects for Inflammatory and Immune Diseases
0849339995, 9780849339998
Purinergic P1 Receptors
Adenosine A2B Receptors
Adenosine A2A Receptors
Purine Nucleosides
G-Protein-Coupled Receptors
Pharmacology, Toxicology and Pharmaceutics(all)
Immunology and Microbiology(all)
Haskó, G., & Szabó, C. (2006). Regulation of monocyte/macrophage function by adenosine receptors. In Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases (pp. 49-68). CRC Press.
Regulation of monocyte/macrophage function by adenosine receptors. / Haskó, G.; Szabó, Csaba.
Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases. CRC Press, 2006. p. 49-68.
Haskó, G & Szabó, C 2006, Regulation of monocyte/macrophage function by adenosine receptors. in Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases. CRC Press, pp. 49-68.
Haskó G, Szabó C. Regulation of monocyte/macrophage function by adenosine receptors. In Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases. CRC Press. 2006. p. 49-68
Haskó, G. ; Szabó, Csaba. / Regulation of monocyte/macrophage function by adenosine receptors. Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases. CRC Press, 2006. pp. 49-68
@inbook{e9fe9681f0f94917b8e25762b04ba31d,
title = "Regulation of monocyte/macrophage function by adenosine receptors",
abstract = "Adenosine is an endogenous purine nucleoside that, subsequent to its release from cells or after being generated extracellularly, diffuses to the membrane of surrounding cells, in which it binds to specific cell surface structures that recognize it, termed adenosine receptors. There are four types of adenosine receptors, all of which are members of the G-protein-coupled family of receptors. They are the A1, A2A, A2B, and A3 adenosine receptors. 1-4 Although adenosine is present at low concentrations in the extracellular space, metabolically stressful conditions increase its extracellular levels dramatically. Adenosine receptors are expressed abundantly on cells of the monocyte/macrophage lineage, and through these receptors adenosine exerts substantial modulatory effects on monocyte/macrophage function. 5-7 Because macrophages are activated by stressful stimuli such as inflammation, hypoxia, and ischemia, the same stimuli that can result in accumulation of extracellular adenosine, adenosine receptors expressed on macrophages represent a sensor system providing macrophages with essential information about the inflammatory or ischemic environment. 6 This mechanism allows macrophages to fine-tune their responses to stressful stimuli. In this chapter, we focus on the consequences of adenosine receptor engagement on monocyte and macrophage function. We will delineate the effect of stimulating the various adenosine receptor subtypes on macrophage differentiation/proliferation, phagocytosis, membrane protein expression, and mediator production. A more complete understanding of the regulation of monocyte/macrophage function by adenosine receptor engagement should help develop novel therapeutic ways of manipulating disorders that are associated with exuberant or insufficient macrophage activation.",
author = "G. Hask{\'o} and Csaba Szab{\'o}",
booktitle = "Adenosine Receptors",
T1 - Regulation of monocyte/macrophage function by adenosine receptors
AU - Haskó, G.
AU - Szabó, Csaba
N2 - Adenosine is an endogenous purine nucleoside that, subsequent to its release from cells or after being generated extracellularly, diffuses to the membrane of surrounding cells, in which it binds to specific cell surface structures that recognize it, termed adenosine receptors. There are four types of adenosine receptors, all of which are members of the G-protein-coupled family of receptors. They are the A1, A2A, A2B, and A3 adenosine receptors. 1-4 Although adenosine is present at low concentrations in the extracellular space, metabolically stressful conditions increase its extracellular levels dramatically. Adenosine receptors are expressed abundantly on cells of the monocyte/macrophage lineage, and through these receptors adenosine exerts substantial modulatory effects on monocyte/macrophage function. 5-7 Because macrophages are activated by stressful stimuli such as inflammation, hypoxia, and ischemia, the same stimuli that can result in accumulation of extracellular adenosine, adenosine receptors expressed on macrophages represent a sensor system providing macrophages with essential information about the inflammatory or ischemic environment. 6 This mechanism allows macrophages to fine-tune their responses to stressful stimuli. In this chapter, we focus on the consequences of adenosine receptor engagement on monocyte and macrophage function. We will delineate the effect of stimulating the various adenosine receptor subtypes on macrophage differentiation/proliferation, phagocytosis, membrane protein expression, and mediator production. A more complete understanding of the regulation of monocyte/macrophage function by adenosine receptor engagement should help develop novel therapeutic ways of manipulating disorders that are associated with exuberant or insufficient macrophage activation.
AB - Adenosine is an endogenous purine nucleoside that, subsequent to its release from cells or after being generated extracellularly, diffuses to the membrane of surrounding cells, in which it binds to specific cell surface structures that recognize it, termed adenosine receptors. There are four types of adenosine receptors, all of which are members of the G-protein-coupled family of receptors. They are the A1, A2A, A2B, and A3 adenosine receptors. 1-4 Although adenosine is present at low concentrations in the extracellular space, metabolically stressful conditions increase its extracellular levels dramatically. Adenosine receptors are expressed abundantly on cells of the monocyte/macrophage lineage, and through these receptors adenosine exerts substantial modulatory effects on monocyte/macrophage function. 5-7 Because macrophages are activated by stressful stimuli such as inflammation, hypoxia, and ischemia, the same stimuli that can result in accumulation of extracellular adenosine, adenosine receptors expressed on macrophages represent a sensor system providing macrophages with essential information about the inflammatory or ischemic environment. 6 This mechanism allows macrophages to fine-tune their responses to stressful stimuli. In this chapter, we focus on the consequences of adenosine receptor engagement on monocyte and macrophage function. We will delineate the effect of stimulating the various adenosine receptor subtypes on macrophage differentiation/proliferation, phagocytosis, membrane protein expression, and mediator production. A more complete understanding of the regulation of monocyte/macrophage function by adenosine receptor engagement should help develop novel therapeutic ways of manipulating disorders that are associated with exuberant or insufficient macrophage activation.
BT - Adenosine Receptors


text:
Sony and Microsoft partner up to make better cloud gaming
Cats and dogs. Batman and the Joker. Xbox and PlayStation. Some rivalries seem too insurmountable to overcome, but that last one might be easing up a bit as Sony and Microsoft have announced a new partnership to improve "customer experiences in their direct-to-consumer entertainment platforms and AI solutions."
In more concrete terms, the companies will jointly explore cloud development through Microsoft's Azure technology to improve streaming services for games and other content. Sony already runs a cloud-based game streaming service with PlayStation Now, and Microsoft has been talking up its own streaming efforts in a big way over the past year.
According to the press release, "the two companies will explore the use of current Microsoft Azure datacenter-based solutions for Sony's game and content-streaming services. By working together, the companies aim to deliver more enhanced entertainment experiences for their worldwide customers." Additionally, the companies plan to collaborate on AI and semiconductor technologies.
Following the announcement, Xbox chief Phil Spencer tweeted that he's "excited about the opportunities ahead with Sony for us to pursue our mutual gaming ambitions and delight players around the world."
This isn't quite the dramatic end to the console wars that forum dwellers have spent years anticipating, but it does indicate that the companies behind Xbox and PlayStation feel like they can work better together. Just don't expect to see an Xstation or PlayBox anytime soon.
Read more: Check out the biggest upcoming PC games
Google Stadia is set to launch later this year, and every major player in the game industry is looking to get cloud gaming right. We're going to see plenty more varied takes on the technology hit the market very soon.
Halo Infinite release date
Halo Infinite E3 2019
Halo: The Master Chief Collection PC


The Poop Factory is a company that sells Poop Chocolate, which is exactly what it sounds like: chocolate that's in the shape of the poop emoji. You can buy a box for $18 which includes 9 Poop Chocolates. Waiwaiwait — just $18 for 9 chocolates shaped like poop?????? That is a steal! A real bargain.
Thank you to Benjamin for sending in the tip. He signed off his email with "Hi Brittany High!!" which I have never ever heard before.


text:
Dick Polman on the Path to 9/11 and Partisan Hypocrisy 0
I present this with the proviso that I had no position on the CBS film about Ronald and Nancy Reagan. For one thing, I was going through a divorce which consumed a lot of energy; for another, I can't remember the last time that I watched a major network television show that didn't involve a ball of some kind.
But I do have a thing about liars and lying. And with presenting as fact something directly contrary to the historical record.
Furthermore, as I have said in a comment to another post here, freedom of speech does not mandate an obligation to publish. The Constituion of the United States of American says that "Congress shall make no law . . . abridging the freedom of speech, or of the press."
This provision, which is reflected in most, if not all, state constitutions (I'm too lazy to do the research) restrains the government; it does not compel individuals or the press.
The argument used by some liberals that the CBS film about the Reagans had to be shown because not showing it somehow violated freedom of speech was, frankly, hogwash. Any similar argument advanced to support the broadcast of "The Path to 9/11" is, similarly, hogwash.
Just as a newspaper has no obligation to publish every letter to the editor or every story off the AP wire, a broadcaster has no obligation to air a show. It is the government which is restrained from prohibiting individuals, the press and, by extension, broadcasters, to express themselves.
Freedom of speech is not compulsion to speak.
A newspaper and a broadcaster–and bloggers, too–are obligated to ensure that what they publish is as accurate as possible and that the line between fact and opinion is clearly drawn–and area where many bloggers, I fear, have a lot to learn.
And now to excerpts from Mr. Polman's comments (emphasis added):
The current flap over the upcoming ABC docudrama The Path to 9/11 is a textbook case of partisan hypocrisy. And that label applies to liberal and conservatives alike.
Let's start with the liberals — not all liberals, of course; I am referring to activists and bloggers — since they're the ones who are ticked off at ABC. Their outrage is directed at various fictionalizations of the 9/11 saga that the Hollywood types have either dreamed up or improvised.
Looking at this case on the merits, it's clear that the liberal camp does have a legitimate beef; even ABC has admitted taking some dramatic liberties with the known facts. But I don't recall the liberal camp acting with similar concern back in 2003, when a CBS docudrama about Ronald Reagan was planning to take some dramatic liberties in its depiction of the former president.
Quite the contrary, in fact. Liberals thought that the Reagan show should air just as the miniseries producers intended it to air — in the name of freedom of speech.
Most conservatives, however, are also selective in their outrage. They don't seem very concerned that the Hollywood types (whom they generally dislike) have filmed fictionalized scenes that depict a former president in a negative light.
Yet the scene was very different in October 2003, when they were so outraged that Hollywood had filmed fictionalizeed scenes depicting their favorite former president in a negative light. Back then, when a major network acted in this fashion, it was viewed as fresh evidence of liberal-media perfidy.
As Ed Morrow of the National Review said, "Attempts to distort our history must be resisted. Historical truth is simply too valuable to be made a plaything for biased filmmakers rewriting it to fit their politics." . . .
September 10, 2006 | Posted by: Frank | Posted in: Uncategorized | Bookmark this post
« Honoring 9/11 . . . with Lies
Lies, Damned Lies, and the Current Federal Administration »


Pop Sick Revintage dream jeans from the 90s. These real vintage beauties survived in great condition. We cut out the pockets to get this sweet look. Featuring a zip closure, skinny legs & two pockets at back. Made of a slightly stretchy fabric.


text:
Store visits
Retailers/Coles/News
Coles news
First <
Coles maintains strong growth in first half
Coles has reported half year sales up 4.7% to AU$18,333m in the 27 weeks to 30 December 2012. Strong growth was maintained across the half with an improving growth trend in Q2 for almost all of Wesfarmers' retail divisions. Food & Liquor continues to grow volume ahead of sales Coles' Food and Liquor sales grew to AU$14,301m in the half, with sales up 5.0% or 3.8% on a like-for-like (LFL)...
Coles launches new private label
As the retailer looks to reinvigorate growth in its liquor formats in 2013, Coles has launched a new private label brand into the beer category. Three ales all with their own Aussie personality Coles has entered the craft beer market with the launch of its own private label branded beer. The new Steamrail Brewing Company brand has the slogan of 'Ale with a Tale', claiming that behind every...
New Finance Director at Coles
Following the departure of Tony Buffin, Coles have appointed Rob Scott as its new finance director. Internal appointment shows strong management pipeline Rob Scott will move from his current position as Managing Director of Wesfarmers insurance, to head up the finance division at Coles . The move follows the decision of outgoing Coles Finance Director, Tony Buffin to take a senior role a...
Coles introduces new price cuts
In order to help customers save money, Coles has slashed the prices of over 100 products, its largest round of price cuts since it launched the Down Down campaign in 2010. Everyday private label products slashed in price Coles has invested tens of millions of dollars in cutting the prices of over 100 everyday products. Coles says that the new cuts are in response to research that it con...


text:
Filed Under: Desumachi, Web Novel on Wednesday, January 13, 2016 zweindrei
11-18. Oni
Satou's here. Speaking of goblins, they're standard beings in fantasy works along with Orcs and Kobolds, but they're originally a normal fairy that likes to jest and do mischiefs.
Come to think of it, they're depicted as intellectual midgets in the story of the super famous magician boy.
"Oops, stop the car here. Yuika would get angry if you damage the flower garden."
After finishing the sightseeing flight, we hurried the vehicle in order to make it in time for Ban's katana smith demonstration, but the course was changed with a few words from Semeri, "Stop by at Yuika's place."
There is no way I can refuse the person who's given me a feast for my eyes with the wonderful wild dance reflected on the back mirror.
Of course Armor didn't object too.
"I will wait here, you two go ahead."
"What? Armor won't go?"
"The young Yuika would cry again if I did."
What's this, is Goblin Yuika a Mrs with a child?
I had arbitrarily imagined that a female shut-in would be a shy unmarried woman.
"I should have prepared some sweets if I knew there was a child."
"Hm? Yuika isn't a child y'know? However, she does like sweet things, so you should bring her some if you come again."
Huh? Our conversation doesn't match.
"Doesn't she have a child?"
"She doesn't y'know? Ban-sama told me that Yuika has 『Multiplepersonality』."
"It's multiple personality. When Yuika experiences painful things, she will leave the memory in the old personality and then change into a newly created personality. It's a story that sounds like it comes from manga, but it's the truth."
It seems the old personality is like the spirit on your back, they can only be a spectator.
When the main Yuika personality sleeps, it seems they can posses her and resurface.
It's a setting that was often used in old manga and anime.
In a sense, it's like how high-elves like Aze-san use the world tree, but this Yuika can do it herself.
While leaving the Armor to house-sit, we advance through the flower garden.
Of course, since I don't want to trample the multicolored flowers that are in full bloom in this flower garden, I fly above the ground with Sky Drive while carrying Semeri under my arm.
"Kuro, the violet flowers over there are shaped in hexagram right? Please land on the center there."
In accordance to Semeri's instruction, I land on the ground.
There's probably an area that's similar to the Corpse's museums nearby here.
"So, where do we enter?"
"We don't. Wait a minute."
Since Semeri is greatly inhaling air, I quickly cover my ears.
As expected, she began to shout, "Yuika", in loud voice. Noisy.
The call seems to be a replacement for the intercom, the flowers that have shaped the hexagram begin to shine lightly, and then six semi-transparent doors appear floating in the light.
The doors are written in characters from Earth, five of them are written with, "A Miss", "Going to Hell", "It's a trap", "Don't enter", and "DEATH".
And then, the last one is "Welcome".
I personally think that all of them seem to be a trap.... But my [Crisis Perception] skill and [Trap Discovery] skill tell me that only the "Welcome" is safe.
"Err, I believe this one should be correct!"
Semeri pointed at "Going to Hell", full of confidence.
I catch the neck of Semeri who was going to dive straight to the hell's door with a bold face, stopping her.
"What're you doing!"
"That one's wrong."
"How do you know?!"
I didn't answer, and dived to the "Welcome" gate while bringing Semeri along.
"Oh! It's really correct! You're amazing Kuro!"
When I asked the frolic Semeri how she usually did it, she answered that she would repeat until she got the correct one.
It seems she would turn into mist or bat when she fails to get away and then repeat it.
She was vexed since it usually took her four tries before she hit the correct one.
"Why won't the other party meet you instead?"
"Yuika is a 『Niit』, so she absolutely won't come out she said."
Shouldn't it be called a shut-in instead of Neet I wonder.
That aside, just as I've expected, this is an [Area without Map] like Corpse's museums.
When I check this are with All Map Exploration, there's no one here besides us.
"There's no one here?"
"Yeah, Yuika is timid, so we won't arrive until another eight of the same gate."
So it's ninth power of six in total--around 10.000.000s I guess?
How cautious.
After traveling through nine gates, we finally arrive at the space where Yuika is.
There are a Japanese house with with a small field and bamboo thicket nearby.
Chickens are pecking their fodder in the courtyard facing the veranda, onions and radishes are hung on the eaves.
I use [All Map Exploration] magic, and acquire the information about Yuika.
Just as Corpse's said, Yuika's race is [Little Oni-kin (Goblin)]. I had expected it to be written as 'High Goblin', but it was the normal one.
By the way, [Little Oni-kin (Goblin)] is not the [Youma] (ghost/apparition) kind that usually appears in fantasy stories, but a [Fairy Tribe] that's like the elves.
Her age is the same as Corpse, but I'm not insensitive enough to fuss over a woman's age.
Compared to Aze, there's no great difference between everyone.
Unexpectedly, her level is only 50.
She doesn't have any normal skill or gift, but her unique skills are ludicrous.
Starting with the [Create My Garden] skill that's created this space, there are 13 of them--almost twice as much even compared to the Dog-head Demon Lord.
Even if she's undergone inflations, this too much.
I cursed the gods that I hadn't even met yet.
"I've come! Yuika!"
Semeri calls toward the Japanese residence with cheerfulness that break the atmosphere of this place.
"Semeri? I've made some delicious takuan. Take it back to Onii-chan Ban okay."
"Geh, takuan is a no no. Ban-sama's beauty would turn yellow."
Yuika who opened the sliding door and came out talked to Semeri with a refreshing voice that doesn't match her age.
Impossible--it's a beautiful girl?!
White transparent skin, silk-like lustrous straight violet hair that extends to the floor.
Although she's not at Lulu's level, she's beautiful enough to rival Arisa's and Mia's beauty.
She would have looked like a human if it were not for her slightly pointed ears that resembled an elf's, and two small horns on her forehead near the temples of her head.
Her slender delicate body lacks undulation like the elf's, but that point is whatever since I'm not into little girls.
"Mou, it's the taste of Japan--"
It seems Yuika has finally noticed me.
She didn't at first due to Semeri's impact, but Yuika's violet pupils have caught sight of me.
Her expression looks happy for an instant, but then her face freezes while still smiling.
Hmm? I didn't hear about her hating men or something.
I had a feeling that her mouth which was flapping slightly spoke "Ichirou".
However, the words that actually reach my ears are different.
"--Infinite Chain"
Purple ripples surround Yuika's body.
The crisis perception reacts like never before.
Countless small black dots appear around Yuika.
They became jet black bullets that assailed me all at once.
One of it is only as big as a bead ball, but AR indicator tells me that those jet black bullets are micro blackholes.
I surely would have been swallowed if I was late activating Flash Drive even a little.
I opened my mouth to ask for the reason, but the jet black bullets that are being endlessly created by Infinite Chain chase after me, puncturing huge hole on ground of the course where I was running away with Flash Drive.
I think Semeri who was late at escaping has been swallowed, but a vampire princess she is should be alright.
She likely would complain about it later, but she probably would forgive me if I gave her a magic sword.
I wanted to converse with Yuika, but my words don't reach as the jet black bullets swallowed it.
I'd like to talk with [Telephone] magic, but this magic won't connect if the other party reject it.
I want the advanced magic [Force Telephone].
I destroy the chasing jet black bullets with [Break Magic], but the other party isn't losing at creating more.
I could make the initiative with [Laser] and [Implosion] if the other party were a demon lord, but I can't do that to a beautiful girl.
Normally, she should have depleted her magic power by now, but her [Mana Loop] and [Mana Spring] unique skills have probably optimized and supplied her magic power.
Dang you cheat.
Just how many unique skills does she use in parallel.
Since three violet ripples are stroking Yuika's body, though I don't know their nature, she's probably using three kind of unique skills.
I wonder if she's alright doing such rashness?
In order to break the deadlock, I close in from her blind spot, and strike Yuika with my palm to make her faint
--that was the trigger of it all.
I should have escaped with all my power.
However, it's too late now.
My careless action becomes the impetus that brings forth [The Worst Demon Lord] who can use 13 kind of Unique Skills, surpassing the Dog-head Demon Lord who was fit to be called an Evil God.
The Goblin Demon Lord, [White Oni Sovereign], was born that day.
Death March kara Hajimaru Isekai Kyousoukyoku 11 SS 9